August 18th, 2020 | 06:00 CEST
BioNTech, CureVac, Valeo Pharma - who is the Covid-19 winner?
The two German companies BioNTech and CureVac have already provided investors with a considerable boost in share prices. The companies have come into the public eye in recent months because they are working on a vaccine against Covid-19 and have already made great progress. Worldwide, these two companies belong to the elite in research and are a beacon of hope in the fight against the corona pandemic. While BioNTech has been listed on the stock exchange for some time, CureVac made its stock market debut last Friday - with success. Investors who have so far missed their entry in these companies should have Valeo Pharma at least on their watch list.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
US09075V1026 , NL0015436031 , CA91915B1085
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Vaccine promises sales boost
The capital market places great hope in German life science companies. The market value of BioNTech is now over USD 16 billion and the newcomer to the stock exchange, CureVac, has already achieved a market capitalisation of over EUR 11 billion. For those who have not yet joined, Valeo Pharma is probably the next big opportunity for share price gains. The market value of the Canadian pharmaceutical company is currently CAD 73 million, which is still a long way from the billion-dollar valuation of the two German companies that are already involved with Covid-19.
Market launch in Canada with Valeo Pharma?
It will certainly only be a matter of time before Valeo Pharma launches a Covid-19 product in Canada. The company is focused on launching drugs in Canada. Biotech companies that have developed a drug in other parts of the world can then launch it in the North American country with Valeo Pharma. The pharmaceutical company does not conduct any research itself and is focused on licensing, approval and distribution of new drugs - which saves time and money. The company's representatives have direct access to doctors and can present new drugs and their effects to decision-makers without wastage.
Expertise for the Canadian market
While European pharmaceutical companies focus on the huge US market and US companies supply products to the EU market, Canada, with its 35 million or so inhabitants, is not in the industry's central focus because its large neighbour has more than ten times as many citizens. The big pharmaceutical giants still have their own sales force in Canada, but the smaller drug manufacturers use companies like Valeo to get the drugs to market.
Covid-19 vaccine in distribution
The special feature of Valeo Pharma is that around 70% of its shares are held by management, employees and insiders. Around CAD 8 million to finance the company has flowed into the cash box from these circles, which should indicate a high level of motivation. Valeo Pharma currently has eight products in its portfolio and six more in the pipeline. In view of the dynamics surrounding Covid-19, it should come as no surprise that the pharmaceutical company's employees will in future also be carrying vaccines against corona viruses in order to flush sales and profits into the cash register.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
